Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vulnerability of anterior medial temporal lobe subregions to early tau-related neurodegeneration in Alzheimer's disease: Converging evidence from tau-PET and plasma p-tau217.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Effects of Task-Irrelevant Talker Identity and Continuity on Spatial Selective Attention Under Interruption.

Trends in hearing·2026
Same author

Uncovering distinct spatiotemporal trajectories of T-N mismatch subtypes with likely co-pathology in Alzheimer's disease using event-based modeling.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Medial temporal lobe Tau-Neurodegeneration mismatch from structural imaging and plasma biomarkers.

Brain : a journal of neurology·2026
Same author

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers.

Annals of neurology·2026
Same author

Surface Inspection and Description in Metrology and Tribology-Vol. 2.

Materials (Basel, Switzerland)·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

Technology and Dementia Preconference.

Dawn Mechanic-Hamilton1, Valerie Humphreys2, Danielle Hing2

  • 1Penn Alzheimer's Disease Research Center, University of Pennsylvania, Philadelphia, PA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 23, 2025
PubMed
Summary
This summary is machine-generated.

This pilot study demonstrates the usability of the mobile cognitive app performance platform (mCAPP) for remote cognitive assessment in patients with Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD) undergoing anti-amyloid therapies (AATs). The app shows promise for tracking cognitive changes during treatment.

More Related Videos

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

Related Experiment Videos

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

Area of Science:

  • Neurology
  • Digital Health
  • Cognitive Science

Background:

  • Engaging mobile cognitive assessments are crucial for monitoring treatment efficacy and safety, especially with new anti-amyloid therapies (AATs).
  • Existing methods may not fully capture cognitive changes or patient engagement during AAT.
  • Remote monitoring is increasingly important for patient convenience and data collection.

Purpose of the Study:

  • To evaluate the feasibility and usability of the mobile cognitive app performance platform (mCAPP) for at-home cognitive assessment.
  • To collect remote cognitive performance data in patients with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease (AD) undergoing AAT.
  • To assess the initial reliability and validity of mCAPP measures.

Main Methods:

  • A pilot study involving 11 participants (MCI or mild AD, amyloid-positive) undergoing AAT.
  • Participants used the gamified mCAPP app both in-clinic and at home for up to three months.
  • Data collected included mCAPP performance, technology use questionnaires, and traditional neuropsychological tests.

Main Results:

  • Participants engaged consistently with mCAPP (1-3 sessions/week at home) with good usability ratings (7.1/9).
  • Task difficulty was perceived as appropriate by most participants.
  • mCAPP tasks demonstrated sensitivity to cognitive load and showed correlations with some standard cognitive measures.

Conclusions:

  • mCAPP is a usable tool for in-clinic and at-home cognitive assessment in patients receiving AAT.
  • Initial findings suggest mCAPP has reliability and validity for tracking cognitive performance.
  • Future research will focus on longitudinal analysis and practice effects.